Business Wire

 QCT, Radisys and Intel Deliver vRAN Solution for 5G

Share

Quanta Cloud Technology (QCT), a global data center solution provider, announced OmniRAN, its virtualized radio access network (vRAN) solution developed with its long-term partners, Intel and Radisys. The solution uses Intel FlexRAN , a cloud-enabled wireless access virtual network functions reference implementation, and Radisys Connect 5G RAN software, a disaggregated RAN architecture for promoting 4G, 5G and IoT to build a cloud-native vRAN based on 3rd Gen Intel Xeon Scalable Processors running on QCT EGX63IS-1U servers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210629005459/en/

To deliver low-latency and power-efficient services with the flexibility to increase or decrease capacity based on the volume of real-time traffic demands, Intel’s vRAN dedicated accelerator, ACC100, for forward error correction (FEC) acceleration is also an essential part of the integrated solution. Intel’s 5G optimized network adapter, codenamed Westport Channel, is also implemented for accurate time synchronization without the added complexity or expenses that come with specialty timing hardware. This validated combination on QCT EGX63IS-1U extends distributed unit (DU) capabilities to support multi-cell and multi-RRU 5G scenarios, delivering reliable performance for various network workloads.

As operators are increasingly looking for ways to accelerate their 5G network deployments by leveraging disaggregated and open reference architecture solutions, OpenRAN-based OmniRAN is designed to minimize the challenges of infrastructure deployment and maximize value of ownership. OmniRAN has already been successfully deployed in smart manufacturing use cases such as safety AI for environment control, high-resolution streaming for quality control, AR goggles for maintenance and repair, and autonomous guided vehicles (AGV) for equipment transport. Not only does OmniRAN provide improved performance such as wider coverage and enhanced mobility, but also offer centralized management as well as greater scalability and deployment flexibility while achieving significant cost savings.

“QCT works closely with its partners to ensure that customers can always stay ahead of the game,” said Mike Yang, President of QCT. “Incorporating the newest technologies and features from Intel and Radisys, QCT’s latest vRAN solution improves capital and operational efficiencies by optimizing resource utilization and making software-defined management and orchestration possible.”

“Open 5G networks are the next step for customers across many sectors, and Radisys, along with our partners, is providing open, disaggregated and virtualized RAN solutions to meet varying business demands,” said Munish Chhabra, head of Mobility Software and Services Business, Radisys. “We are excited to power the QCT vRAN solution through our market first Release 16 Radisys 5G software stack. The integrated solution enables mobile operators and enterprises to benefit from reduced costs, improved network efficiencies, and faster time-to-market of new services that open APIs and open architectures provide.”

“This demonstration from Intel, QCT, and Radisys is important for accelerating broader adoption of 5G,” said Cristina Rodriguez, Intel VP and GM of Data Center Group, Wireless Access Network Division. “By defining the FlexRAN reference architecture and collaborating with our Intel Network Builders, Intel is expanding its growing portfolio of technology and ecosystem to ensure interoperability, enhanced performance, and reduced overhead for service providers all over the globe.”

For more information visit https://go.qct.io/telco/.

About Quanta Cloud Technology (QCT)

Quanta Cloud Technology (QCT) is a global data center solution provider. We combine the efficiency of hyperscale hardware with infrastructure software from a diversity of industry leaders to solve next-generation data center challenges. QCT serves cloud service providers, telecoms and enterprises running public, hybrid and private clouds.

Intel, the Intel logo and other Intel marks are trademarks of Intel Corporation or its subsidiaries. Other names and brands may be claimed as the property of others.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Danny Chang
Danny_Chang@quantatw.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kyowa Kirin Provides Update on Application for Marketing Authorisation of Istradefylline in Europe for the Treatment of ‘OFF’ Episodes in People Living with Parkinson’s23.7.2021 17:05:00 EEST | Press release

Kyowa Kirin Co., Ltd. (TSE:4151, President and CEO: Masashi Miyamoto, “Kyowa Kirin”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion for istradefylline as an add-on treatment to levodopa (L-Dopa) based regimens in adults living with Parkinson’s, experiencing end-of-dose motor fluctuations. Kyowa Kirin International remain committed to istradefylline and people living with Parkinson’s and are currently reviewing the options available, which may include re-examination. “We are disappointed by the CHMP opinion. However, we remain confident in the benefit-risk profile of istradefylline and are committed to making a difference to the lives of people living with Parkinson’s, an area which has had few innovative therapies for decades,” said Abdul Mullick, President of Kyowa Kirin International. “There are currently few new treatment options available to manage end-of-dose motor fluctuations in Parkinson

ForumPay Teams Up with Bambora to Conquer the Crypto-to-Fiat Payments Market23.7.2021 16:16:00 EEST | Press release

ForumPay, an international cryptocurrency-to-fiat payment service provider, has established a partnership with the global payments provider Bambora, a Worldline brand, to bring seamless crypto payment solutions to merchants and online shoppers. The partnership will cater to a large global audience and offer expanded payment options for both shoppers and merchants. ForumPay continues its march to dominate the growing crypto payments ecosystem for merchants around the world. “ForumPay provides merchants with a seamless, secure and instant processing solution to accept payments from the more than 54 million active crypto wallet users around the world. By providing a payments service for processing crypto into fiat that functions as naturally as card payments, ForumPay enables merchants with a familiar feeling payments alternative that also gives them a competitive advantage by tapping into the fastest growing consumer base on the planet.” says Joshua Tate, CEO of ForumPay. “We are very ex

Wipro Recognized as 2021 Microsoft Modernizing Applications Partner of the Year23.7.2021 15:54:00 EEST | Press release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that it has won the 2021 Microsoft Partner of the Year Award in the Modernizing Applications category. In addition, Wipro was also named as a category finalist in the 2021 AI Partner of the Year category, solidifying its reputation as an innovator in multiple sectors. This recognition highlights Wipro’s deep expertise and ability to go above and beyond for its customers, powered by an established partnership with Microsoft. Even when working with complex customer environments, spanning across hundreds of servers with different applications of different versions, Wipro was able to help customers meet their business needs and leverage the power of public cloud in an efficient way. “Global enterprises have embraced modernization at an unprecedented scale and pace, and the demands of the past year show no sign of easing. We are honor

Merck Announces Appointment of Head of China & International for Healthcare23.7.2021 14:45:00 EEST | Press release

Merck, a leading science and technology company, today announced that Hong Chow will join its Healthcare business sector as Head of China & International on October 1. In this role at Merck, Chow will lead China, Japan as well the regions Europe, Latin America, Asia-Pacific and Middle East, Africa and Russia, the franchise of Cardiovascular Metabolism & Endocrinology (CM&E), and the Global Business Innovation team. Chow will report to Peter Guenter, Member of the Executive Board of Merck and CEO Healthcare. She will serve as a member of the Healthcare Executive Committee, and be based in Shanghai, China. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210723005186/en/ Merck Announces Appointment of Head of China & International for Healthcare (Photo: Business Wire) “Hong’s international experience and strong track record of bringing innovative medicines to patients in need across both developed and emerging markets, most nota

H.I.G. WhiteHorse Refinances Grupo Recoletas23.7.2021 14:03:00 EEST | Press release

H.I.G. WhiteHorse, a credit affiliate of global investment firm H.I.G. Capital ("H.I.G.") is pleased to announce that it has arranged a refinancing package for Grupo Hospitalario Recoletas (“Recoletas”), which includes a significant growth capital component. Recoletas is a family-owned Spanish private hospital operator headquartered in Valladolid, Spain, with a leading position in the Castilla y Leon Spanish inland region. It operates 8 hospitals with c. 540 beds and 13 medical centres across 7 regions. H.I.G. WhiteHorse has committed €110 million in unitranche loans to refinance the borrower's existing indebtedness and provide additional capital to finance growth, supporting the Company’s expansion. Recoletas is currently developing ambitious projects to expand its healthcare services provided through hospitals and medical centers, as well as diagnostic imaging centers and radiotherapy units. Amando J. Rodríguez, President and CEO of Grupo Hospitalario Recoletas, said: “We are very ha

Schlumberger Announces Second-Quarter 2021 Results23.7.2021 13:50:00 EEST | Press release

Schlumberger Limited (NYSE: SLB) today reported results for the second-quarter 2021. Second-Quarter Results (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2021 Mar. 31, 2021 Jun. 30, 2020 Sequential Year-on-year Revenue* $5,634 $5,223 $5,356 8% 5% Income (loss) before taxes - GAAP basis $542 $386 $(3,627) 40% n/m Net income (loss) - GAAP basis $431 $299 $(3,434) 44% n/m Diluted EPS (loss per share) - GAAP basis $0.30 $0.21 $(2.47) 43% n/m Adjusted EBITDA** $1,198 $1,049 $838 14% 43% Adjusted EBITDA margin** 21.3% 20.1% 15.6% 118 bps 561 bps Pretax segment operating income** $807 $664 $396 22% 104% Pretax segment operating margin** 14.3% 12.7% 7.4% 162 bps 694 bps Net income, excluding charges & credits** $431 $299 $69 44% 525% Diluted EPS, excluding charges & credits** $0.30 $0.21 $0.05 43% 500% Revenue by Geography International $4,511 $4,211 $4,224 7% 7% North America* 1,083 972 1,097 11% -1% Other 40 40 35 n/m n/m $5,634 $5,223 $5,356 8% 5% *Schlum

Wyss Center Partners With Artiria Medical to Accelerate a Novel Therapy for Cerebral Vasospasm23.7.2021 12:59:00 EEST | Press release

The Wyss Center and Artiria Medical today announced a new partnership to accelerate the translation of a novel technology that has the potential to reduce deaths and improve quality of life for stroke patients. Artiria Medical, an early-stage medical device company focused on disruptive neurovascular products, has been developing the technology and is now joining forces with the Wyss Center, a non-profit organization dedicated to bringing state-of-the-art therapies to the patient. The team has received support from the Swiss Innovation Agency, Innosuisse, to test and validate the efficacy of the therapy preclinically, in preparation for human clinical studies. Stroke is the third leading cause of disability worldwide with more than 80 million people living with long-term impairments as a result. Some strokes result in bleeding in the brain. Such hemorrhagic strokes can lead to severe cerebral vasospasm - an uncontrolled contraction of brain arteries - in the days that follow, depriving

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom